27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
PVeD reproducibly contextualized associations between plasma pTau217 and PET-defined Alzheimer pathology across cohorts with different participant composition, pTau217 assays, PET tracers, and cognitive measures. 2 key findings →
Participants: 602 Evidence: low
Full summary, score breakdown and related studies → Original source
A prespecified structure–reserve–glial profile captured reproducible cognitive variation beyond measured Alzheimer disease molecular pathology across two cohorts. 1 key finding →
Design: longitudinal study Participants: 436 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Complement-mediated neuroinflammation has been implicated in Alzheimer’s disease (AD), but its role during the pre-symptomatic phase of the disease remains unclear. 4 key findings →
Participants: 708 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Amyloid-β and tau, pathological hallmarks of AD, silently accumulate years before clinical symptoms’ onset and are associated with neuronal dysfunction and cognitive impairment. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Brain perfusion SPECT revealed AD-typical hypoperfusion patterns and demonstrated modest potential to estimate the presence or absence of Aβ deposition with left parietal rCBF. 5 key findings →
Participants: 88 Evidence: low
Full summary, score breakdown and related studies → Original source
Ninety-six non-artifactual Amyloid-Tau components were identified, of which 73 showed appreciable spatial correspondence between their paired Amyloid and Tau maps, while 17 were Tau-localized and 6 Amyloid-localized. 2 key findings →
Participants: 320 Evidence: low
Full summary, score breakdown and related studies → Original source
This study investigated whether WM measures derived from amyloid-PET are associated with AD biomarkers and to determine whether they offer added diagnostic and prognostic value beyond established biomarkers. 5 key findings →
Participants: 320 Evidence: low
Full summary, score breakdown and related studies → Original source
Diffusion MRI (dMRI) enables assessment of white matter microstructural abnormalities in Alzheimer's disease (AD), and multisite datasets enable more robust modeling of non-biological variation that can confound analyses. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
RNT was associated with increasing global amyloid accumulation even after controlling for psychological symptoms (B = 0.0120, 95% Confidence Interval 0.003 to 0.021, P = 0.012), and in sensitivity analyses limited to participants aged ≥50 or ≥60. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Foundation models have driven major advancements in the language and vision domains, as seen in the popularity of Artificial Intelligence (AI) tools, and a growing number of studies are bringing the approach to human brain imaging. 2 key findings →
Participants: 343 Evidence: low
Full summary, score breakdown and related studies → Original source
: Treated patients were 74±7 years old; 57% were female, 59% were apolipoprotein E ε4 carriers, and 78% had mild cognitive impairment (22% mild dementia). 5 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease and cerebral amyloid angiopathy are characterized by the accumulation of amyloid-β (Aβ) species, yet the human fluid-physiological mechanisms that regulate soluble Aβ transport and clearance remain poorly understood. 3 key findings →
Participants: 502 Evidence: moderate
Full summary, score breakdown and related studies → Original source
As the world's population ages, Alzheimer's disease (AD), a progressive neurodegenerative disorder, is becoming more common. 1 key finding →
Participants: 59 Evidence: low
Full summary, score breakdown and related studies → Original source
Residualized WMH T1w/T2w-FLAIR ratio captures lesion-specific microstructural variation missed by volumetric measures, consistent with vascular-gliotic injury in VD and coexisting amyloid-linked demyelination in AD. 4 key findings →
Design: cross-sectional Participants: 71 Evidence: moderate
Full summary, score breakdown and related studies → Original source
DPM is fundamentally constrained by dynamic range, variability, and test–retest reliability of the biomarker of interest. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Semi-supervised multimodal fusion improves prediction and reveals interpretable imaging patterns that predict APOE4 and clinical diagnoses better than traditional approaches. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder, and early diagnosis is essential for timely intervention. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The social, structural, and physical conditions in which individuals live, work, and age, collectively termed social determinants of health (SDOH), are associated with risk of Alzheimer's disease and related dementias (ADRD). 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Neuropsychiatric symptoms (NPS) are highly prevalent in Mild Cognitive Impairment (MCI), conceptualized as an intermediate clinical state between normal aging and dementia. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The choroid plexus (ChP) is a highly vascularized structure located in the brain ventricles that plays important roles in multiple central nervous system functions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The basal forebrain is an early site of pathology in Alzheimer’s disease (AD). 3 key findings →
Design: longitudinal study Participants: 116 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Sleep disturbances are pervasive in Lewy body disorders (LBD), but their neurophysiological basis remains unclear. 1 key finding →
Participants: 109 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) pathology is increasingly recognized to manifest in the retina, offering a non-invasive window for early biomarker discovery. 2 key findings →
Design: longitudinal study Participants: 40 Evidence: moderate
Full summary, score breakdown and related studies → Original source
NODDI-derived ODI is associated with tau PET signal, even in preclinical disease and may discriminate individuals with-and without tau beyond the MTL. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The overall incidence of any ARIA was 25.2%, with ARIA-H occurring in 22.4% of patients and ARIA-E in 12.2%. 3 key findings →
Design: cohort study Participants: 468 Evidence: moderate
Full summary, score breakdown and related studies → Original source
9 of the 2,885 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →